Skip to main content
SpringerLink
Log in

Support Drugs

  • Chapter
  • First Online:
The Golden Guide to Oncologic Pharmacy

  • 619 Accesses

Abstract

The drugs used to treat neoplasms are considered systemic treatments and thus they can reach any cell in the body, especially those proliferating quickly, thus leading to adverse effects so feared by patients. Toxicity will depend on several factors, including the condition of the individual, stage of the disease, and also the drugs used (Burille et al., Manejo e enfrentamento dos efeitosadversospelosclientesemtratamentoquimioterápico. RevistaCiência, Cuidado e Saúde, 7. https://periodicos.uem.br/ojs/index.php/CiencCuidSaude/article/view/6707 Accessed on 29/06/2021, 2013). Upon the points discussed, it is possible to understand that there is a need to expand knowledge regarding the management of adverse effects experienced by patients undergoing chemotherapy. The purpose is to assist them properly because they can present several adverse effects in varying degrees of intensity (Soares et al., CogitareEnferm, 14(4):714–719, 2009). The drugs offered as support are essential in managing these effects, helping to improve the quality of life of patients and greater adherence to cancer treatment (França et al., Einstein, 13(2):221–225, 2015).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Weiss RB, Baker JR. Hypersensitivity reactions from antineoplastic agents. Cancer Metas Rev. 1987;6:413–32.

    Article  CAS  Google Scholar 

  2. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol. 1990;8(7):1263–1268 9782.

    Article  CAS  PubMed  Google Scholar 

  3. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist. 2007;12(5):601–9.

    Article  CAS  PubMed  Google Scholar 

  4. Calogiuri G, Ventura MT, Mason L, et al. Hypersensitivity reactions to last generation chimeric, humanized, and human recombinant monoclonal antibodies for therapeutic use. Curr Pharm Des. 2008;14:2883–91.

    Article  CAS  PubMed  Google Scholar 

  5. Dillman RO. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev. 1999;18:465–71.

    Article  CAS  PubMed  Google Scholar 

  6. Brennan PJ, Bouza TR, Hsu FI, Sloane DE, Castells MC. Hypersensitivity reactions to mABs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol. 2009;124(6):1259–66.

    Article  CAS  PubMed  Google Scholar 

  7. Ream MA, Tunison D. Hypersensitivity reactions. In: Yasko JM, editor. Nursing Management of Symptoms Associated with chemotherapy. Meniscus Health Care: Bala Cynwyd; 2001. p. 213–24.

    Google Scholar 

  8. Darmon M, Malak S, Guichard I, Schlemmer B. Acute tumor lysis syndrome: a comprehensive review. Rev Bras Ter Intensiva. 2008;20(3):278–85.

    Article  PubMed  Google Scholar 

  9. Locatelli F, Rossi F. Incidence and pathogenesis of tumor lysis syndrome. Contrib Nephrol. 2005;147:61–8.

    CAS  PubMed  Google Scholar 

  10. Montesinos P, Lorenzo I, Martín G, et al. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica. 2008;93(1):67–74.

    Article  CAS  PubMed  Google Scholar 

  11. Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with highgrade non-Hodgkin’s lymphoma. Am J Med. 1993;94(2):133–9.

    Article  CAS  PubMed  Google Scholar 

  12. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364(19):1844–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Tallo FS, Vendrame LS, Lopes RD, Lopes AC. Síndrome da lise tumoral: umarevisão para o clínico. Rev Bras Clin Med. São Paulo. 2013;11(2):150–4.

    Google Scholar 

  14. Solh M, Appel J. Tumor lysis syndrome. Hosp Physician. 2008;44:25–9.

    Google Scholar 

  15. Tosi P, Barosi G, Lazzaro C, et al. Consensus conference on the management of tumor lysis syndrome. Hema. 2008;93(12):1877–85.

    Google Scholar 

  16. Coiffier BA, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008;26(16):2767–78.

    Article  CAS  PubMed  Google Scholar 

  17. Montoya L. Managing hematologic toxicities in the oncology patient. J Infus Nurs. 2007;30(3):168–72.

    Article  PubMed  Google Scholar 

  18. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: fever and neutropenia. Available at: http://www.nccn.org/professionals/physician_gls/PDF/fever.pdf. Accessed 13 June 2021.

  19. Foubert J. Cancer-related anaemia and fatigue: assessment and treatment. Nurs Stand. 2013;20(36):50.

    Google Scholar 

  20. Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med. 1990;322(24):1689–92.

    Article  CAS  PubMed  Google Scholar 

  21. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997;34(3):13–9.

    CAS  PubMed  Google Scholar 

  22. Kuter DJ. Managing thrombocytopenia associated with câncer chemotherapy. Oncology. 2015;29(4):282.

    PubMed  Google Scholar 

  23. Klastersky J, Paesmans M, Rubenstein EB, et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18(16):3038–51.

    Article  CAS  PubMed  Google Scholar 

  24. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Bone Marrow Transplant. 2009;44(8):453–5.

    Article  CAS  PubMed  Google Scholar 

  25. Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst R. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer. 2011;11(1):1–11.

    Article  CAS  Google Scholar 

  26. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer. 2004;40(15):2201–16.

    Article  CAS  PubMed  Google Scholar 

  27. Organização Pan Americana de SaúdeBrasil. Folha informativa – Câncer. https://www.paho.org/bra/index.php?option=com_content&view=article&id=5588:folha-informativa-cancer&Itemid=1094. Acessoem 22 de julho.

  28. O’Brien BJ, Rusthoven J, Rocchi A, Latreille J, Fine S, Vandenberg T, Laberge F. Impact of chemoterapy – associated nausea and vomiting on patients functional status and on costs: survey of five Canadian centers. Can Med Assocj. 1993;149(3):296–302.

    Google Scholar 

  29. Fresco DR, Suárez L. Recomendaciones para la prevención y eltratamento de náuseas y vómitosinducidos por quimioterapia. Revista Medica del Uruguay. 2004;20(2):120–9.

    Google Scholar 

  30. Hu Z, Liang W, Yang Y, et al. Personalized estimate of chemoterapy-induced nausea and vomiting: development and external validation of a nomogram in cancer patients receiving highly/moderately emetogenic chemoterapy. Medicine. 2016;95(2) https://journals.lww.com/md-journal/Fulltext/2016/01120/Personalized_Estimate_of_Chemotherapy_Induced.58.aspx Accessed July 22.

  31. Becker J, Nardin JM. Use of antiemetics in the antineoplastic treatment of cancer patients. R Bras Farm Hosp Serv Saúde São Paulo. 2011;2(3):18–22.

    Google Scholar 

  32. Almeida RGL, Pontes ACAA, Cardoso DA, Carrera JS, Sousa MS, Maia SF. O Manejo da ÊmeseemumaUnidadeOncológica: a Necessidade da IntervençãoFarmacêuticaem Tempo Real. RevistaBrasileira de Cancerologia. 2015;61(2):115–21.

    Article  Google Scholar 

  33. Aapro M, Jordan K, and Feyer P. 2013. Pathophysiology of chemotherapy-induced nausea and vomiting. https://link.springer.com/chapter/10.1007%2F978-1-907673-58-0_2.

    Google Scholar 

  34. National Comprehensive Cancer Network (NCCN) Guidelines. Antiemesis, version 1.2019, 2019.

    Google Scholar 

  35. Grunberg SM, Deuson RR, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer. 2004;100(10):2261–8.

    Article  PubMed  Google Scholar 

  36. Guia para notificação de reaçõesadversasemoncologia/SociedadeBrasileira de FarmacêuticosemOncologia – SOBRAFO, Agência Nacional de VigilânciaSanitária – ANVISA. 2. ed. São Paulo: ConectfarmaPublicaçõesCientíficas; 2011.

    Google Scholar 

  37. Barrios DM, Phillips GS, Freites-Martinez A, et al. Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study. J Eur Acad Dermatol Venereol. 2020;34(6):1340–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Lacouture ME, Sibaud V, Gerber PA, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆. Ann Oncol. 2021;32(2):157–70.

    Article  CAS  PubMed  Google Scholar 

  39. Nardone B, Nicholson K, Newman M, et al. Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitop.rs in cancer patients. Clin Cancer Res. 2010;16:4452–60.

    Article  CAS  PubMed  Google Scholar 

  40. Saad ED, Hoff PM, Carnelós RP, et al. Comun toxicity criteria of the National Cancer Institute. Revista Brasileira de Cancerologia. 2002;48(1):63–96.

    Article  Google Scholar 

  41. Lichtenberger BM, Gerber PA, Holcmann M, et al. Epidermal EGFR controls cutaneous host defense and prevents inflammation. Sci Transl Med. 2013;5:111.

    Article  CAS  Google Scholar 

  42. Roe E, Garcia Muret MP, Marcuello E, et al. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. J Am Acad Dermatol. 2006;55:429–37.

    Article  PubMed  Google Scholar 

  43. Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011;19:1079–95.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Zhao CY, Liu RC, Consuegra G, et al. Epidermal growth factor receptor inhibitor-induced papulopustular eruption successfully treated with low-dose oral dapsone. Australas J Dermatol. 2018;59:219–20.

    Article  Google Scholar 

  45. Jo SJ, Shin H, Jo S, et al. Prophylactic and therapeutic efficacy of pyridoxine supplements in the management of hand–foot syndrome during chemotherapy: a meta-analysis. Clin Exp Dermatol. 2015;40(3):260–70.

    Article  CAS  PubMed  Google Scholar 

  46. Zhang RX, Wu XJ, Wan DS, et al. Celecoxib can prevent capecitabine related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. Ann Oncol. 2012;23:1348–53.

    Article  CAS  PubMed  Google Scholar 

  47. Miller KK, Gorcey L, McLellan BN. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol. 2014;71:787–94.

    Article  PubMed  Google Scholar 

  48. Dummer R, Ascierto PA, Gogas HJ, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, openlabel, randomised, phase 3 trial. Lancet Oncol. 2018;19:1315–27.

    Article  CAS  PubMed  Google Scholar 

  49. Anforth R, Fernandez-Penas P, Long GV. Cutaneous toxicities of RAF inhibitors. Lancet Oncol. 2013;14:11–8.

    Article  CAS  Google Scholar 

  50. Zielinski C, Lang I, Beslija S, et al. Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer. Br J Cancer. 2016;114:163–70.

    Article  CAS  PubMed  Google Scholar 

  51. Stintzing S, Fischer von Weikersthal L, Vehling-Kaiser U. et al., Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial. Br J Cancer. 2011;105(2):206–11.

    Google Scholar 

  52. Freites-Martinez A, Azael. The MASCC textbook of cancer supportive care and survivorship. New York: Springer International Publishing; 2018. p. 2018.

    Google Scholar 

  53. Sibaud V, Leboeuf NR, Roche H, et al. Dermatological adverse events with taxane chemotherapy. Eur J Dermatol. 2016;26:427–43.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Stander S, Weisshaar E, Mettang T, et al. Clinical classification of itch: a position paper of the international forum for the study of itch. Acta Derm Venereol. 2007;87:291–4.

    Article  PubMed  Google Scholar 

  55. Monroe EW. Relative efficacy and safety of loratadine, hydroxyzine,and placebo in chronic idiopathic urticaria and atopic dermatitis. ClinTher. 1992;14:17–21.

    CAS  Google Scholar 

  56. Robert C, Sibaud V, Mateus C, et al. Nail toxicities induced by systemic anticancer treatments. Lancet Oncol. 2015;16:181–9.

    Article  CAS  Google Scholar 

  57. Kiyohara Y, Yamazaki N, Kishi A. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer. J Am Acad Dermatol. 2013;69:463–72.

    Article  CAS  PubMed  Google Scholar 

  58. Piraccini BM, Bellavista S, Misciali C, et al. Periungual and subungual pyogenic granuloma. Br J Dermatol. 2010;163:941–53.

    Article  CAS  PubMed  Google Scholar 

  59. Capriotti K, Capriotti JA. Chemotherapy-associated paronychia treated with a dilute povidone-iodine/dimethylsulfoxide preparation. Clin CosmetInvestig Dermatol. 2015;8:489–91.

    CAS  Google Scholar 

  60. Capriotti K, Capriotti J, Pelletier J, et al. Chemotherapy-associated paronychia treated with 2% povidone-iodine: a series of cases. Cancer Manag Res. 2017;9:225–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Cubiro X, Planas-Ciudad S, Garcia-Muret MP, et al. Topical timolol for paronychia and pseudopyogenic granuloma in patients treated with epidermal growth factor receptor inhibitors and capecitabine. JAMA Dermatol. 2018;154:99–100.

    Article  PubMed  Google Scholar 

  62. Mirshams M, Daneshpazhooh M, Mirshekari A, et al. Cryotherapy in the treatment of pyogenic granuloma. J Eur Acad Dermatol Venereol. 2006;20:788–90.

    CAS  PubMed  Google Scholar 

  63. Winther D, Saunte DM, Knap M, et al. Nail changes due to docetaxelda neglected side effect and nuisance for the patient. Support Care Cancer. 2007;15:1191–7.

    Article  PubMed  Google Scholar 

  64. Garden BC, Wu S, Lacouture ME. The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis. J Am Acad Dermatol. 2012;67:400–8.

    Article  CAS  PubMed  Google Scholar 

  65. Minisini AM, Tosti A, Sobrero AF, et al. Taxane-induced nail changes: incidence, clinical presentation and outcome. Ann Oncol. 2003;14:333–7.

    Article  CAS  PubMed  Google Scholar 

  66. Thomas R, Williams M, Cauchi M, et al. A double-blind, randomised trial of a polyphenolic-rich nail bed balm for chemotherapy-induced onycholysis: the UK polybalm study. Breast Cancer Res Treat. 2018;171:103–10.

    Article  CAS  PubMed  Google Scholar 

  67. Kim JY, Ok ON, Seo JJ, et al. A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant/adjuvant docetaxel chemotherapy. Breast Cancer Res Treat. 2017;164:617–25.

    Article  CAS  PubMed  Google Scholar 

  68. Scotte F, Tourani JM, Banu E, et al. Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol. 2005;23:4424–9.

    Article  PubMed  Google Scholar 

  69. Scotte F, Banu E, Medioni J, et al. Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer. 2008;112:1625–31.

    Article  PubMed  Google Scholar 

  70. Bossi P, Antonuzzo A, Cherny NI, et al. ESMO guidelines committee. Electronic address: clinicalguidelines@esmo.org. Diarrhea in adult cancer patients: ESMO clinical practice guidelines. Ann Oncol. 2018;29(4):126–42.

    Article  Google Scholar 

  71. Andreyev J, Ross P, Donnellan C, et al. Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncol. 2014;15(10):447–60.

    Article  Google Scholar 

  72. Benson AB III, Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004;22(14):2918–26.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmacy, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil

    Gabriela Sandoval da Silva & Taynna Tatiane Pereira

  2. Pharmacy, Hospital Salvalus (Grupo NotreDame Intermédica), São Paulo, SP, Brazil

    Lygia Leão Fernandes

Authors
  1. Gabriela Sandoval da Silva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lygia Leão Fernandes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Taynna Tatiane Pereira
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pediatric Oncology Pharmacist & Writer, Curitiba, Paraná, Brazil

    Carolina Witchmichen Penteado Schmidt

  2. Jesus Maria José Maternity Hospital, Quixadá, Ceará, Brazil

    Kaléu Mormino Otoni

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

da Silva, G.S., Fernandes, L.L., Pereira, T.T. (2022). Support Drugs. In: Schmidt, C.W.P., Otoni, K.M. (eds) The Golden Guide to Oncologic Pharmacy. Springer, Cham. https://doi.org/10.1007/978-3-030-98596-7_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-98596-7_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-98595-0

  • Online ISBN: 978-3-030-98596-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation